Another win for CogState

By Dylan Bushell-Embling
Tuesday, 12 August, 2008

CogState [ASX: CGS] has signed a contract worth $1.2 million which will see the company provide technology to a major pharmaceutical company for use in a Phase III schizophrenia study.

The cognition specialist company will be providing its computerised cognitive testing technology for the trial, which is to be conducted in over 70 sites.

This is the ninth contract the company has signed since July.

The nine contracts have a combined value of $2.3 million, and CogState is expecting that 63 per cent of the contracts' revenue will be earned in the coming financial year.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd